• Why the Mesoblast share price has soared 310% in the last 3 months

    woman testing substance in laboratory dish, csl share price

    Mesoblast limited (ASX: MSB) has been one of the standout performers on the ASX over the past three months. The company’s share price dropped as low as $1.02 on 23 March amid the economic fallout from the coronavirus pandemic.

    Since then, however, the Mesoblast share price has really soared and is currently trading at $4.18. That’s a massive 310% growth in the company’s share price in just three months. This includes a 4.5% increase so far today.

    Mesoblast has become a world leader in developing allogeneic, off-the-shelf, cellular medicines. The ASX listed biotech has successfully leveraged its proprietary cell therapy technology to establish a range of commercial products and late-stage product candidates.

    So, what is behind this strong recent rally in the Mesoblast share price?

    Helping win the fight against coronavirus

    It’s pretty likely that the recent rise of the Mesoblast share price is linked to some promising progress the company is making with its treatment for COVID-19 patients.

    In early May, Mesoblast commenced Phase 2/3 trials in the United States of its remestemcel-L treatment. The trials encompassed patients with moderate to severe coronavirus symptoms who required ventilator support.

    The trial achieved an 83% survival rate and reported that 75% of patients managed to come off ventilator support within a ten day period. The remestemcel-L product works by counteracting the inflammatory process in the lungs caused by COVID-19. These initial encouraging results were first revealed back in late April at a New York hospital.

    Further encouraging results were revealed at the end of May. Phase 2 trial results concluded that remestemcel-L, given in four monthly intravenous doses, significantly improved the outcome for patients with inflammatory lung disease, such as that suffered by COVID-19 patients.

    Strong financial performance

    Mesoblast’s recent financial performance has also been strong.

    The company recorded an 113% increase in overall revenues to US$31.5 million for the first 9 months of FY 2020, compared to the prior corresponding period.

    Mesoblast also recorded a 127% increase from milestone revenues involving strategic partnerships.

    Where to now for the Mesoblast share price?

    With the Mesoblast share price rising by over 300% in the last few months, only time will tell if it can continue this strong performance moving forward. Judging by today’s price, the market is likely expecting further promising clinical trial results to come from this dual listed biotech.

    For more exciting growth shares like Mesoblast, check out the following report.

    5 ASX stocks under $5

    One trick to potentially generating life-changing wealth from the stock market is to buy early-stage growth companies when their share prices still look dirt cheap.

    Motley Fool’s resident tech stock expert Dr. Anirban Mahanti has identified 5 stocks he thinks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why the Mesoblast share price has soared 310% in the last 3 months appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/30Wr7TV

  • Australian retail sales up 16.3% in May

    Pile of sporting equipment against a white background

    Australian retail sales surged 16.3% in May to $4.03 billion. This is the largest month-on-month rise in 38 years. The release by the Australian Bureau of Statistics showed a surge in sales right across the retailing industry. This is good news for retail ASX shares and the broader economy. 

    However, does this mark a turning point that ASX retailers had been dreaming about? Let’s begin with a dive into the impact on retail shares and the economy.

    Impact on retail ASX shares

    Wesfarmers Ltd (ASX: WES) will benefit as hardware, building and garden supplies, clothing, electronic goods and footwear experienced large increases in sales. This is good news for its Bunnings, Target, Kmart and Officeworks brands. 

    Similarly, JB Hi-Fi Limited (ASX: JBH) and Harvey Norman Holdings Limited (ASX: HVN) will benefit from sales increases in household goods. Products such as furniture, floor covering, houseware, textile goods, electrical and electronic goods saw an increase in turnover. 

    In addition, there is positive news for supermarkets owned by Woolworths Group Ltd (ASX: WOW), Coles Group Ltd (ASX: COL) and Metcash Limited (ASX: MTS) with food retailing rising solidly. 

    Impact on the economy

    A rise in retail sales is good news for the broader economy as it illustrates consumers are feeling more optimistic about their finances. Government intervention in terms of Jobkeeper and Jobseeker could also explain the spark for retail sales. Increased foot traffic to retailers is also marked by the easing of restrictions. Also, strong retail sales is a positive development for jobs in the industry.

    Does this mark a turning point for Australian retail?

    Many retailers are hoping so. Unfortunately, the 16.3% increase in May follows a 17.7% fall in April.  More light will be shed on whether there is a recovery playing out in the industry as retail data is released over the coming months.   

    The shift in how we work and study could also explain the surge in retail sales.  Working and studying from home has prompted a sharp rise in demand for office-related furniture and equipment. Furthermore, the reduction in time travelling to work meant we have more time to do DIY projects at home. This may shift with a return back to the office.

    While the strong rebound in retail sales is excellent news for the ASX retailers mentioned above, cautious optimism is needed. Jobkeeper has an estimated expiry date of September which will be a hit to consumers discretionary income and Jobseeker payment is set to revert back to levels pre-crisis. As a result, the consumer’s optimism may quickly evaporate and tighten their wallets. 

    Not convinced by retail? How about these shares instead…

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Matthew Donald owns shares of Harvey Norman Holdings Ltd. and Wesfarmers Limited. The Motley Fool Australia owns shares of COLESGROUP DEF SET, Wesfarmers Limited, and Woolworths Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Australian retail sales up 16.3% in May appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2UXRQeG

  • What’s next for these 4 ASX travel shares?

    plane flying across share markey graph, asx 200 travel shares, qantas share price

    Despite some relaxation of coronavirus restrictions, travel remains largely off the cards. This is impacting the ASX travel shares, which have seen mixed recoveries since the market meltdown in March. 

    Borders were closed in late March in an effort to combat coronavirus. According to the Australian Bureau of Statistics (ABC), overseas arrivals in March fell 60%, with just 331,900 short term visitors arriving in Australia. Overseas arrivals to Australia collapsed in April following the border closures, with ABS data revealing that overseas visitors decreased 99.3% to just 2,200 trips (compared to March). The Australian tourism industry, which was already hurting from the summer bushfires, began to sustain heavy economic damage. 

    ASX travel shares fell out of favour with investors in late February as the scope of the pandemic became clearer. While there is hope Australians will be able to travel between states in the coming weeks, international travel may be off the cards until next year. Some estimate it may take up to 3 years for international travel to return to pre-COVID levels.

    With this in mind, we take a look at how the ASX travel shares are travelling. 

    Corporate Travel Management Ltd (ASX: CTD)

    The Corporate Travel Management share price has bounced over 160% from its March low, but remains 44% down from its 2020 high. The travel agent is one of the few that has not yet raised capital to shore up the liquidity. 

    Corporate Travel benefits from its business  model in which a high proportion of costs are variable. With a small physical footprint, the business saves on rent with about 70% of costs people-related. This enabled a swift resizing of the business. 

    When the crisis hit, Corporate Travel Management embarked on a comprehensive cost reduction program. The company’s cost base has been reduced to $10–$12 million a month, down from $27–$27 million a month. This has been achieved through a combination of retrenchment, temporary stand downs, government initiatives such as JobKeeper, the elimination of non-essential expenditure and reduced capex. 

    Domestic travel restrictions are likely to ease prior to international restrictions. This will benefit Corporate Travel, which is leveraged to the domestic market – about 60% of its total transaction volumes are domestic in nature. Domestic activity is highly profitable for Corporate Travel, particularly in Australia/New Zealand and Europe. 

    Corporate Travel Management is positioning itself for a domestic recovery. It says it has the ability to operate a high performing domestic only business with a reduced cost base until international recovers. Staff capacity in each region is ready to be deployed back to full time as required. 

    Flight Centre Travel Group Ltd (ASX: FLT)

    The Flight Centre share price is up 55% from its March low but remains down 65% from 2020 highs. The travel operator closed stores and raised emergency funds in the wake of the pandemic. It raised $700 million in equity to provide liquidity during the coronavirus crisis. 

    Flight Centre is aiming to reduce its cost base to $65 million per month by the end of July 2020. Prior to COVID-19, the cost base was around $226 million a month. CEO Graham Turner says the equity raising and cost saving initiatives will enable Flight Centre to trade through the current period of global disruption to the travel industry. 

    To reduce costs by 70%, Flight Centre is closing half its stores and reducing its workforce. The cost saving measures will themselves cost the company $210 million in redundancies, lease breakages and the like. 

    Travel shutdowns meant Flight Centre’s total transaction value fell to a low of 20% of normal levels in March. Uncertainty around how long travel restrictions will remain in place means Flight Centre will want a buffer of funds to protect its business in the interim. 

    The equity raising and additional funding lines give Flight Centre around $1.6 billion in additional liquidity. This should fund the company well into 2021 with minimal revenues before a significant uplift in business will be required. 

    Qantas Airways Limited (ASX: QAN)

    The Qantas share price has risen 107% from its March low but remains nearly 40% down from its earlier highs. The airline has extended flight cancellations from May through to the end of July. Capacity can be added back if domestic and Trans-Tasman restrictions ease. 

    Qantas raised $1.05 billion in debt funding secured against seven Boeing 787-9s in March. It has now secured an additional $550 million in funding secured against three wholly owned 787-9s. Net debt is $5.8 billion, which is in the middle of the airline’s target range. Qantas has no financial covenants on its debt facilities and no significant debt maturities until June 2021. 

    Qantas says it has sufficient liquidity to respond to a range of recovery scenarios, including where conditions persist until December 2021. It also has $2.7 billion in unencumbered aircraft assets and can raise funds against these if required. 

    Qantas acted quickly to slow cash burn early in the crisis. This was achieved through employee stand downs, revised agreements with suppliers, and pauses on virtually all capital and operating expenditures based on current conditions, Qantas expects to reach a net cash burn rate of $40 million per week by the end of June 2020. 

    The airline is currently operating around 5% of its pre-crisis domestic passenger network and 1% of its international network. 

    Regional Express Holdings Ltd (ASX: REX)

    Regional Express Holdings shares are trading on par with levels pre-coronavirus. Shares in the airline operator were boosted by speculation it could start flying between capital cities. This would see Regional Express compete with Qantas and Virgin Australia. 

    Regional Express said it is considering the feasibility of commencing domestic airline operations. This would involve flying between capital cities and not just to them. The airline has been approached by several parties interested in providing the equity needed for it to start regional operations in Australia. 

    The airline estimates it would need $200 million to expand its operations. According to the Australian Financial Review (AFR), the business plan would involve leasing 10 narrow-bodied jets. With airlines globally struggling due to the travel downturn, Regional Express should be able to access aircraft at distressed prices. 

    With a sufficient capital injection, the Regional Express board believes, “there is a confluence of circumstances which render the start of domestic operations by Rex to be a particularly compelling proposition.” If the board decides to proceed with the expansion, domestic operations are expected to commence on 1 March 2021. 

    3 “Double Down” Stocks To Ride The Bull Market

    Motley Fool resident tech stock expert Dr. Anirban Mahanti has stumbled upon three under-the-radar stock picks he believes could be some of the greatest discoveries of his investing career.

    He’s so confident in their future prospects that he has issued “double down” buy alerts on each of these three stocks to members of his Motley Fool Extreme Opportunities stock picking service.

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Kate O’Brien has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Corporate Travel Management Limited. The Motley Fool Australia has recommended Flight Centre Travel Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post What’s next for these 4 ASX travel shares? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3hK8TdY

  • Is the Woolworths share price a buy?

  • Cloudflare Sees Uptick in Cyber Attacks as Internet Usage Increases

  • SpringWorks (SWTX): A Rare Cancer Biotech with Potentially >50% Upside. Recommending BUY.

  • Which markets or industries do you see perform best in the next decades (geographic vs. industry focus vs. cap size)? How do you build this into a strategy and portfolio to maximize expected risk-adjusted future returns?